The constituents from the needles of the pine tree, Pinus densiflora, were purified and investigated for antithrombotic activity. The needles were initially extracted three times with 70% ethanol, and the extract was sequentially fractionated with chloroform and n-butanol. The aqueous layer formed after n-butanol fractionation was subjected to purification by medium pressure and high pressure liquid chromatography. The two neolignans, 2, 3-dihydro-7-hydroxyl-3-hydroxymethyl-2-(4´-hydroxyl -3-methoxyphenyl)-5-benzofuranpropanol-3-O-α-rhamnopyranoside (a neolignan glycoside) and 2, 3-dihyro-3-hydroxymethyl-7-methoxy-2-(4´-hydroxyphenyl-3´-methoxy)-5-benxofuran propanol 4´-O-α-rhamnopyranoside (icariside E4) were identified by 1 H and 13 C NMR spectra. The effect of the purified compounds, the neolignan glycoside and icariside E4 on thrombin inhibition were investigated by measuring thrombin clotting time in plasma. As a result, the clotting of the neolignan glycoside was delayed four times compared to that of icariside E4. In addition, an analysis of the inhibition effect by changing the concentration showed that the clotting time was delayed in accordance with an increase in the concentration of the neolignan glycoside. Furthermore, we examined the interaction of thrombin and fibrinogen to clarify the action mechanism. As a result, the delay of clotting time in the response of thrombin and pure fibrinogen may indicate that neolignan glycosides inhibit the thrombin action in a direct manner, leading to the suppression of fibrin generation.
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Introduction
A diversity of lifestyles, such as changes in eating habits and lack of exercise, along with rapid economic growth, has caused habitual diseases such as cardiovascular disease and stroke, which have become a major cause of morbidity and mortality. Although many pathophysiological processes are associated with the chronic development of cardiovascular disease, thrombosis is one of the causes triggering stroke and acute coronary syndrome. Although anti-platelet agents including aspirin and anticoagulant agents such as heparin and warfarin are candidates for treating thromboembolic diseases, these drugs show many potential limitations. In particular, major ischemic cardiovascular diseases frequently accompany these diseases, and bleeding complications represent a major disadvantage [5, 12, 20] . The contribution of protease-activated receptors (PARs) to coagulation has also been investigated in vivo using antagonists to PAR-1 [24] .
Thrombin is a serine protease catalyzing cleavage of fibrinogen and other clotting factors, leading to activation of the coagulation system and the platelet response. This reaction allows thrombin to play an integral role in hemostasis and thrombosis. The constituents from Pinus densiflora Sieb et Zucc (Pinaceae). have been purified in search of potential candidates for an antithrombotic agent. P. densiflora, is found abundantly in mountainous regions of Korea, Japan, and China [12] . Pine needles have been traditionally used in Korean medicine for suppressing liver and gastroenteric problems, as well as skin diseases [10, 11, 12, 16] . The chemical constituents, including essential oils (α-pinene, β-pinene, camphene, phellandrene, limonene, borneol, and bornyl acetate), cinnamic acid, and benzoic acid have thus far been reported in the Pinus genus [13, 14, 15] . Previous studies have reported chemical constituents with antioxidant activity, including 5,7,8,4'-tetrahydroxy-3-methoxy-6-methylflavone-8-O-β-D-glucopyranoside, kaempferol 3-O-galactopyranoside and its 6''-acetate, (+)-isolarisiresinol xylopyranoside, and (+)-catechin [1, 7, 8] .
In this study, two unique constituents from P. densiflora were newly identified and investigated for a putative antithrombotic agent candidate.
Materials and Methods
Plant, chemicals and instruments P. densiflora needles were collected at Youngwol, Gangwondo, Korea in April 2012 and were authenticated by the Korea Environmental and Ecological Services. Plasma 
Extraction and purification
The diagrammatic scheme for the extraction of constituents from P. densiflora is shown in Fig. 1 . The powdered needles of P. densiflora (2.4 kg) were refluxed in 70% ethanol for 3 hr (20 l × 3 times). The total filtrate was concentrated to dryness in vacuo at 40°C to render the ethanol extract.
The extract was then suspended in 10 volumes of 5% methanol and partitioned with an equal volume of chloroform.
Each partitioned solvent was concentrated in vacuo and the resulting extracts were analyzed for antithrombotic activity.
The aqueous part of the n-butanol fraction, showing the highest thrombin inhibition activity, was chromatographed on C-18 silica gel medium-pressure liquid chromatography.
The n-butanol fraction was eluted with mobile phase of 20, 40, 60, 80, and 100% methanol sequentially to yield 15 fractions (B1~B15). Thrombin inhibition activities of the isolated fractions were measured, and the B5 fraction representing the highest activity was separated by HPLC to yield seven fractions (B5-1~B5-7). Constituents corresponding to the main peak, the B5-1 (compound 1) and B5-7 (compound 2) fractions, were structural analyzed for further study.
Antithrombotic activity assay Antithrombotic activity measured APTT (activited partial thromboplastin time), PT (prothrombin time) and TT (thrombin time). APTT and PT were measured using a Dade® actin and a Dade® thromboplastin C plus, respectively. Thrombin time was measured by the slight change in turbidity using the method of Born and Cross [15] and a coagulometer (KC-A1, Amelung, Japan). In a tube, 50 μl 0.5 U thrombin and 50 μl 20 mM CaCl2 were mixed with 10 μl of the purified compounds dissolved in DMSO and DMSO (control), and pre-incubated for 2 min at 37°C. Plasma clotting was determined by measuring the time consumed after adding and mixing 100 μl plasma [21] . A 50 μl aliquot of 5 U thrombin and 50 μl of 20 mM CaCl2 were mixed with 10 μl of the purified compounds dissolved in DMSO and DMSO (control), in a coagulometer tube and pre-incubated for 2 min at 37°C. Fibrinogen clotting was determined by estimating the time consumed after adding and mixing 100 μl of 0.33% fibrinogen in the tube. The chemical shift values should show in parenthesis, as report of Nakanishi [21] . A methoxy group was bonded to the C3´residue in the heteronuclear multiple bond correlation (HMBC) and nuclear overhauser effect spectroscopy (NOESY) data (Table 1 ). In addition, a proton peaks originating from a hydrofuran ring were identified in These results demonstrate that compound 1 was identified and characterized as (2S, 3R)-2,3-dihydro-7-hydroxy-3-hydroxymethyl-2-(4´-hydroxy-3´-methoxyphenyl)-5-benzofuranpropanol 3a-O-α-rhamnopyranoside (a neolignan glycoside), which was homologous to the structure and optical rotation value isolated from Juniperus communis [18, 21] . (Fig.   2A ). In addition, three methylene proton peaks based on the hydroxypropyl group were observed in δ 2.60 (2H, t, J = 7.5 Hz, H-5a), δ 1.78 (2H, tt, J = 7.5, 6.5 Hz, H-5b) and δ 3.54 (2H, t, J = 6.5 Hz, H-5c). The proton peaks from the hydrofuran ring were also observed in δ 5.54 (1H, d, J = 6.0 Hz, H-2), δ 3.44 (1H, overlapped, H-3), δ 3.77 (1H, dd, J=10.6, Table 2 and Fig. 2B .
Antithrombotic activities of the compounds Thrombogenesis (coagulation) is the process by which blood clots form, which is an integral part of hemostasis, wherein a damaged blood vessel wall is protected by a platelet and fibrin-containing clot to stop bleeding and begin repair of the damaged vessel. Disorders of thrombogenesis can result in an increased risk of hemorrhage or obstructive clotting (thrombosis) [4] . The effect of the purified compounds, the neolignan glycoside and icariside E4, on thrombin inhibition was investigated by measuring thrombin clotting time in plasma at a final concentration of 500 μg/ml of the compounds. As a result, the clotting times of the neolignan.
that the clotting of the neolignan glycoside was delayed four times compared to that of icariside E4, suggesting that it was more effective for thrombin inhibition (Fig. 3A) . In addition, an analysis of the inhibition effect by changing the concentration showed that the clotting time was delayed in accordance with an increase in the concentration of the neolignan glycoside, suggesting that it works in a concentration-dependent manner (Fig. 3B) . These coagulation factors circulate as inactive zymogens and activate the "final common pathway" of factor X, thrombin, and fibrin [9] . The intrinsic coagulation pathway begins with formation of the primary complex on collagen due to high-molecular-weight kininogen, prekallikrein, and FXII Xa, IXa, XIa, XIIa, and kallikerin, as well as thrombin activities, whereas the heparin cofactor II simply inhibits thrombin activity [6] .
The inhibitory mechanism of the isolated neolignan glycosides was investigated. The coagulation mechanism was examined by APTT (activited partial thromboplastin time) estimation method [23] confirming the inhibition of prothrombin blood coagulation factors Ⅴ, Ⅷ, Ⅸ, Ⅹ, Ⅺ, and Ⅻ activated in the plasma, and PT (prothrombin time) estimation method [22] confirming blood coagulation factors Ⅱ, Ⅴ,Ⅶ, Ⅹ and so on in plasma. As a result, the low level of blood coagulation activity similar to that of control group was significantly detected (data not shown). In addition, as shown in Fig. 4 , analysis of TT (thrombin time) confirming the common pathway factor Ⅱ, Ⅴ, and fibrinogen suggested significantly the inhibition activity of blood coagulation.
Thus, we examined the interaction of thrombin and fibrinogen to clarify the action mechanism (Fig. 4) . As a result, the delay of coagulation time in the response of thrombin and pure fibrinogen may indicate that neolignan glycosides inhibit the thrombin action in a direct manner, leading to the suppression of fibrin generation. The inhibition activity was in accordance with the concentration-dependent manner. These findings suggest that neolignan glycosides, similarly to heparin, do not inhibit the thrombin response resulting from the activation of prothrombin inhibiting the factors in the plasma, but induce the blood coagulation delay by inhibiting the thrombin response of fibrinogen in the plasma. Further studies are needed on the inhibition mode of thrombin and fibrinogen interaction.
